MA39450A1 - Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine - Google Patents

Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine

Info

Publication number
MA39450A1
MA39450A1 MA39450A MA39450A MA39450A1 MA 39450 A1 MA39450 A1 MA 39450A1 MA 39450 A MA39450 A MA 39450A MA 39450 A MA39450 A MA 39450A MA 39450 A1 MA39450 A1 MA 39450A1
Authority
MA
Morocco
Prior art keywords
pharmaceutically acceptable
acceptable salts
medicine
pirlindole
pirlindole enantiomers
Prior art date
Application number
MA39450A
Other languages
English (en)
Other versions
MA39450B2 (fr
Inventor
Filipe Augusto Eugénio Pardal
Pedroso Pedro Filipe Eufrásio
Pecorelli Susana Marques Almeida
Caixado Carlos Alberto Eufrásio Casimiro
Ana Sofia Da Conceição Lopes
João Carlos Ramos Damil
Oliveira Santos Pedro Paulo De Lacerda E
Original Assignee
Tecnimede Soc Tecnico-Medicinal S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Soc Tecnico-Medicinal S A filed Critical Tecnimede Soc Tecnico-Medicinal S A
Publication of MA39450A1 publication Critical patent/MA39450A1/fr
Publication of MA39450B2 publication Critical patent/MA39450B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des sels pharmaceutiquement acceptables de composés de (r)-pirlindole et de (s)-pirlindole énantiomériquement purs, qui présentent un profil de biodisponibilité acrrue et se destinent à un usage médical.
MA39450A 2014-05-09 2014-05-09 Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine MA39450B2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000026 WO2015171002A1 (fr) 2014-05-09 2014-05-09 Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine

Publications (2)

Publication Number Publication Date
MA39450A1 true MA39450A1 (fr) 2017-08-31
MA39450B2 MA39450B2 (fr) 2021-10-29

Family

ID=50819928

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39450A MA39450B2 (fr) 2014-05-09 2014-05-09 Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine

Country Status (29)

Country Link
US (1) US10226460B2 (fr)
EP (2) EP3831385B1 (fr)
JP (1) JP6400121B2 (fr)
KR (1) KR102276281B1 (fr)
CN (1) CN106413713B (fr)
AU (1) AU2014393487B2 (fr)
CA (1) CA2948595C (fr)
DK (1) DK3831385T3 (fr)
EC (1) ECSP16086196A (fr)
ES (1) ES2988983T3 (fr)
FI (1) FI3831385T3 (fr)
HR (1) HRP20241165T1 (fr)
HU (1) HUE068011T2 (fr)
IL (1) IL248852B (fr)
LT (1) LT3831385T (fr)
MA (1) MA39450B2 (fr)
MX (1) MX373227B (fr)
NZ (1) NZ726127A (fr)
PH (1) PH12016502235A1 (fr)
PL (1) PL3831385T3 (fr)
PT (1) PT3831385T (fr)
RS (1) RS65918B1 (fr)
RU (1) RU2706688C2 (fr)
SA (1) SA516380258B1 (fr)
SI (1) SI3831385T1 (fr)
SM (1) SMT202400359T1 (fr)
TN (1) TN2016000495A1 (fr)
UA (1) UA118587C2 (fr)
WO (1) WO2015171002A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2016000498A1 (en) * 2014-05-09 2018-04-04 Tecnimede Sociedade Tecnico Medicinal S (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine.
UA116499C2 (uk) * 2014-05-09 2018-03-26 Текнімеді Сос'Єдаді Текніку-Медісінал С.А. (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
EP3392250A1 (fr) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation de l'anneau de pipérazine pour la synthèse de pyrazinocarbazole
EP3392251A1 (fr) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation des enantiomères de pirlindole et leurs sels

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK170473B1 (da) * 1985-06-20 1995-09-11 Daiichi Seiyaku Co S(-)-pyridobenzoxazinforbindelser
EP1558231A4 (fr) * 2002-10-03 2010-09-08 Cypress Bioscience Inc Escalade posologique et dose quotidienne fractionnee d'antidepresseurs pour traiter des troubles neurologiques
EP1688161A1 (fr) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Utilisation du pirlindole dans le traitement des maladies caracterisées par la prolifération des lymphocytes t et/ou par l'hyperproliferation de kerationcytes, notamment la dermatite atopique et le psoriasis
WO2010068867A1 (fr) * 2008-12-11 2010-06-17 Biovista, Inc. Méthodes de traitement de la sclérose en plaques utilisant des pyrazinoindoles tétracycliques
US20150250808A1 (en) * 2012-10-15 2015-09-10 Vojo P. Deretic Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
RS59499B1 (sr) * 2014-05-09 2019-12-31 Tecnimede Sociedade Tecnico Medicinal S A Proces za dobijanje optički aktivnih enantiomera pirlindola i njihovih soli
TN2016000498A1 (en) * 2014-05-09 2018-04-04 Tecnimede Sociedade Tecnico Medicinal S (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine.
UA116499C2 (uk) * 2014-05-09 2018-03-26 Текнімеді Сос'Єдаді Текніку-Медісінал С.А. (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині

Also Published As

Publication number Publication date
MX2016014704A (es) 2017-05-23
KR20170002433A (ko) 2017-01-06
EP3139926A1 (fr) 2017-03-15
HUE068011T2 (hu) 2024-12-28
KR102276281B1 (ko) 2021-07-13
ES2988983T3 (es) 2024-11-22
IL248852B (en) 2020-05-31
RU2016148174A (ru) 2018-06-14
PL3831385T3 (pl) 2024-10-14
AU2014393487A1 (en) 2016-11-24
TN2016000495A1 (en) 2018-04-04
DK3831385T3 (da) 2024-08-26
CN106413713B (zh) 2020-07-14
SMT202400359T1 (it) 2024-11-15
PH12016502235A1 (en) 2017-01-09
SI3831385T1 (sl) 2024-11-29
RU2016148174A3 (fr) 2018-06-14
CN106413713A (zh) 2017-02-15
HRP20241165T1 (hr) 2024-11-22
PT3831385T (pt) 2024-09-24
RU2706688C2 (ru) 2019-11-20
EP3831385A1 (fr) 2021-06-09
FI3831385T3 (fi) 2024-09-04
SA516380258B1 (ar) 2019-11-04
AU2014393487B2 (en) 2020-01-02
RS65918B1 (sr) 2024-10-31
EP3831385B1 (fr) 2024-07-10
UA118587C2 (uk) 2019-02-11
JP6400121B2 (ja) 2018-10-03
LT3831385T (lt) 2024-09-10
NZ726127A (en) 2019-03-29
US20170143710A1 (en) 2017-05-25
JP2017514882A (ja) 2017-06-08
WO2015171002A1 (fr) 2015-11-12
CA2948595C (fr) 2021-07-13
MA39450B2 (fr) 2021-10-29
IL248852A0 (en) 2017-01-31
ECSP16086196A (es) 2017-02-24
CA2948595A1 (fr) 2015-11-12
US10226460B2 (en) 2019-03-12
MX373227B (es) 2020-04-21

Similar Documents

Publication Publication Date Title
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
MX375639B (es) Derivados de heterociclilos sustituidos como inhibidores de cdk
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201790271A1 (ru) Ингибиторы гликозидазы
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
MX375902B (es) Inhibidores de serina/treonina cinasa.
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2015016495A (es) Compuestos de 3,4-dihidroisoquinolin-2 (1h)-ilo.
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
EA201791021A1 (ru) 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ
MX390051B (es) Antagonistas de ep4.
CA3290933A1 (en) Oral octreotide for the treatment of disease
GB2587172B (en) Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
MA39450A1 (fr) Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine
MX2015013048A (es) Forma cristalina de un compuesto ansiolitico.
MX2018006005A (es) Formulaciones que comprenden sales de oxalato de teneligliptin y solvatos de este.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
HUE053725T2 (hu) Aminotiolészter vegyületek vagy azok gyógyászatilag elfogadható sói, rák kezelésében történõ alkalmazásra
HK40000685A (en) Oral octreotide for the treatment of disease
TH1601007484A (th) สารประกอบเฮเทอโรแอริลสำหรับการยับยั้งไคเนส